{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.5","upperLimit":"6.6","value":"4.4"},{"groupId":"OG001","lowerLimit":"4.5","upperLimit":"17.4","value":"11.5"},{"comment":"The upper bound of 80% CI was not estimable, as 10 (45.5%) participants were censored for no longer being followed for survival","groupId":"OG002","lowerLimit":"14.5","upperLimit":"NA","value":"37.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"description":"OS was defined as duration from the date of randomization to the date of death from any cause. Kaplan-Meier (KM) method was used to estimate median OS. In this method, every participant had a follow-up time which was associated with an indicator, 1=event (death in our case), and 0 =censored. If the participants were not known to have died, time to date of last known to be alive was used as to calculate the follow-up time and indicator was 0 for these participants. KM method estimates the median OS based on the K-M curve. The K-M curve only drops when we had an event and censor data are the ticks in the graph. To estimate median OS, the K-M curve usually will be smoothed first and a line will be drawn at 50%. The median OS is the point when K-M curve and the horizontal hit. Survival status was collected every month for the first 2 months after discontinuation of study treatment and thereafter every 2 months until death or 4 years from each participant's first dose.","dispersionType":"80% Confidence Interval","groups":[{"description":"Included all participants who received oral glasdegib in combination with LDAC in phase 1B portion.","id":"OG000","title":"Phase 1B: Glasdegib + LDAC"},{"description":"Included all participants who received oral glasdegib in combination with decitabine in phase 1B portion.","id":"OG001","title":"Phase 1B: Glasdegib + Decitabine"},{"description":"Included all participants who received oral glasdegib in combination with cytarabine/daunorubicin in phase 1B portion.","id":"OG002","title":"Phase 1B: Glasdegib + Cytarabine/Daunorubicin"}],"paramType":"MEDIAN","populationDescription":"Full analysis set: all enrolled participants of Phase 1B portion who received at least 1 dose of study medication.","reportingStatus":"POSTED","timeFrame":"First dose to Follow-up (4 years)","title":"Overall Survival (OS) at Phase 1B","type":"SECONDARY","unitOfMeasure":"Months"}